Avalyn Pharma enters the second half of June with an unusual split: short sellers are piling in at the fastest pace in months, while major institutional backers are adding aggressively at lower prices.
The short-selling story is the sharpest data point this week. Shares short have climbed roughly 61% over the past week — from around 736,000 to just under 1.18 million — a pace that stands out even for a small-cap pharma name. The ORTEX short score has responded in kind, jumping from roughly 39 in early June to 49.1 today, its highest reading in the observable window. The move is clearly directional: this isn't noise around a stable base, it's a sustained build that started the week of June 9 and has accelerated since.
The borrow market tells a more complicated story. Availability is actually loose by most standards — at around 328%, there are more than three shares available to borrow for every one already lent out, suggesting there is no structural squeeze pressure in the lending pool. Cost to borrow, at 8.2%, is firm but has roughly halved from the 30%-plus levels seen in early May. The combination — rising short interest with comfortable availability — points to bears building new positions deliberately, rather than existing shorts being forced into a squeeze or covering. That said, availability has tightened sharply in recent weeks: it was above 1,600% at end of May and has since compressed to 328%, the tightest level in the data.
The Street's posture is firmly constructive, though the analyst data is now roughly three weeks old. Three firms — Morgan Stanley, Guggenheim, and Evercore ISI — all initiated coverage on May 26 with positive ratings. Guggenheim is the outlier on the upside with an $80 target; Morgan Stanley and Evercore framed their Overweight and Outperform ratings around targets in the low $50s. Against a current price of $28.07, the mean target of $59 implies more than 100% upside — a gap that reflects either deep conviction in the pipeline or the typical post-IPO framing where analysts who backed the company through the raise initiate with wide targets. Avalyn is loss-making (price-to-book runs at roughly 13.8x, all other meaningful multiples are negative), so the valuation case is entirely clinical.
The institutional ownership picture reinforces the analyst tone. In late April and early May, three major holders — Novo Holdings, SR One Capital Management, and Perceptive Advisors — were each reporting their entire stake as a new position, with all changes registered at the May 1 IPO price of $18. Novo and SR One collectively deployed around $20 million at that level, and the top five holders collectively hold more than 34% of shares. For a stock now trading at $28, those are paper gains — but the concentration of specialist biotech and pharma-focused capital (Perceptive, Suvretta, Impresa, Eventide, Wellington all appear in the top ten) speaks to genuine institutional conviction in the clinical thesis rather than passive index buying.
The immediate catalyst is a next earnings event pencilled for early September. With no history of earnings reactions on record — AVLN appears to be a recent listing — the September print will be more about clinical updates and cash runway than anything resembling a traditional beat-or-miss moment. The faster-than-expected build in short interest between now and that date, and whether borrow availability continues to tighten as that positioning grows, is the dynamic worth tracking closely.
See the live data behind this article on ORTEX.
Open AVLN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
